JPRN-UMIN000027005
Recruiting
未知
Treat and extend regimens with intravitreal aflibercept for macular edema secondary to branch retinal vein occlusion - Treat and extend intravitreal aflibercept for branch retinal vein occlusion
Jikei daisan hospital0 sites50 target enrollmentApril 17, 2019
Conditionsbranch retinal vein occlusion
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- branch retinal vein occlusion
- Sponsor
- Jikei daisan hospital
- Enrollment
- 50
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Patients were excluded if they had received treatment such as glaucoma or vitreous surgery and cataract surgery within 3 months; and if they had diabetic retinopathy or central retinal vascular occlusion.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Combination therapy of intravitreal aflibercept and topical bromfenac for RVOretinal vein occlusionJPRN-UMIN000022988Juntendo Urayasu Hospital40
Unknown
Phase 4
Treat and Extend Therapy Study Using Intravitreal Aflibercept for Patients Exited From Protocol VGFT-OD 0910Exudative Age-related Macular DegenerationNCT01961414Palmetto Retina Center, LLC45
Not yet recruiting
Phase 3
To investigate the role of Intravitreal Aflibercept (Eylea) in the treatment of patients whose wet Age related Macular degeneration is not adequately controlled with conventional anti VEGF (intravitreal Avastin or Lucentis) treatment.ACTRN12613001020774Greenlane Clinical Centre Auckland District Health Board50
Not yet recruiting
Not Applicable
Effect of Alternate Treatment with Intravitreal Anti-Vascular Endothelial Growth Factor and Corticosteroid for Macular EdemaKCT0007766Hallym University Medical Center-Kangnam188
Unknown
Phase 1
Intense Treatment Regimen With Intravitreal Aflibercept InjectionNeovascular Age-Related Macular DegenerationNCT03594461Vitreous -Retina- Macula Consultants of New York30